Extramedullary multiple myeloma

References

• Van Rhee F, Anaissie E, Angtuaco E, et al., editors. Williams hematology. 8th ed. New York, NY: McGraw Hill; 2010.
   Google Scholar
• Rajkumar SV, Blood E, Vessole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group. J Clin Oncol 2006;24:431–436.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–2498.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Short KD, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011;25:906–908.
   PubMed Web of Science ®Google Scholar
• Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010; 21:325–330.
   PubMed Web of Science ®Google Scholar
• Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996;93:345–351.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007;92:143–144.
   PubMed Web of Science ®Google Scholar
• Cerny J, Fadare O, Hutchinson L, et al. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol 2008;81:65–69.
   PubMed Web of Science ®Google Scholar
• Pasmantier MW, Azar HA. Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases. Cancer 1969;23:167–174.
   PubMed Web of Science ®Google Scholar
• Blade J, Lust JA, Kyle RA. Immuglobulin D multiple myeloma: presenting features, reponse to therapy, and survival in a series of 53 cases. J Clin Oncol 1994;12:2398–2404.
   PubMed Web of Science ®Google Scholar
• Bartel TB, Haessler J, Brown TL, et al. F-18 fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009; 114:2068–2076.
   PubMed Web of Science ®Google Scholar
• Blade J, Fernandez de Larrea C, Rosinol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011; 29:3805–3812.
   PubMed Web of Science ®Google Scholar
• Chang H, Sloan S, Li D, et al. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004;127:280–284.
   PubMed Web of Science ®Google Scholar
• Sheth N, Yeung J, Chang H. p53 nuclear accumulation is associated with extramedullary progresson of multiple myeloma. Leuk Res 2009;33:1357–1360.
   PubMed Web of Science ®Google Scholar
• Billecke L, Penas EM, May AM, et al. Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma. Anticancer Res 2012;32:2031–2034.
   PubMed Web of Science ®Google Scholar
• Egan JB, Shi CX, Tembe W, et al. Whole genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution and clonal tides. Blood 2012;120:1060–1066.
   PubMed Web of Science ®Google Scholar
• Wang SY, Hao HL, Deng K, et al. Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration. Leuk Lymphoma 2012;53:1162–1168.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Kuehl M, Lodahl M, et al. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005;105:317–323.
   PubMed Web of Science ®Google Scholar
• Blade J, Fernandez de Larrea C, Rosinol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011;29:3805–3812.
   PubMed Web of Science ®Google Scholar
• Hedvat CV, Comezo RL, Teruya-Feldstein J, et al. Insights into extramedullary tumor cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol 2003;122:728–744.
   PubMed Web of Science ®Google Scholar
• Dahl IM, Rasmussen T, Kauric G, et al. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 2002;116:273–277.
   PubMed Web of Science ®Google Scholar
• Chang H, Bartlett E, Patterson B, et al. The absence of CD56 on the malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Br J Haematol 2005;129:539–541.
   PubMed Web of Science ®Google Scholar
• Blade J, Fernandez de Larrea C, Rosinol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011;29:3805–3812.
   PubMed Web of Science ®Google Scholar
• Bink K, Haralambieva E, Kremer M, et al. Primary extramedullary plasmacytoma: similarities and differences with multiple myeloma revealed by interphase genetics. Haematologica 2008;93:623–626.
   PubMed Web of Science ®Google Scholar
• Rasche L, Bernard C, Topp M, et al. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol 2012;91:1031–1037.
   PubMed Web of Science ®Google Scholar
• Raanani P, Shpilberg O, Ben-Bassat I. Extramedullary disease and targeted therapies for hematological malignancies—is the association real?Ann Oncol 2007;18:7–12.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Smallwood L, Smith T, et al. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med 1989;110:521–525.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over represented in high risk disease even in the era of novel agents. Haematologica 2012;97:1761–1767.
   PubMed Web of Science ®Google Scholar
• Blade J, Perales M, Rosinol L, et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001;113:422–424.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Cibeira MT, Blade J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004;89:832–836.
   PubMed Web of Science ®Google Scholar
• Nakazato T, Mihara A, Ito C, et al. Lenalidomide is active for extramedullary disease in refractory multiple myeloma. Ann Hematol 2012;91:473–474.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Cibeira MT, Uriburu C, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006;76:405–408.
   PubMed Web of Science ®Google Scholar
• Oriol A. Multiple myeloma with extramedullary disease. Adv Ther 2011;28(Suppl. 7):1–6.
   PubMedGoogle Scholar
• Wu P, Davies FE, Boyd K, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma 2009;50:230–235.
   PubMed Web of Science ®Google Scholar
• Trullemans F, Schots R, Storme G, Van Camp B. Late and localized extramedullary relapse of light chain kappa myeloma after syngeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25(1):115–7.
   PubMed Web of Science ®Google Scholar
• Chong G, Byrnes G, Szer J, et al. Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant 2000;26:1011–1015.
   PubMed Web of Science ®Google Scholar